Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 Dose Escalation in Overweight and Obesity
NCT06718998Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0519-0130 in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Adverse Events at 18 weeks. Started Nov 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06718998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718998.